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Background: Diabetes is independently associated with increased risk for acute coronary syndrome (ACS). Although presence of thin-fibrous cap is 
a known predictor of ACS, serial changes in fibrous cap thickness in diabetic patients are still unknown.
Objective: The purpose of this study was to investigate serial changes in fibrous cap thickness in diabetic patients.
Methods: A total of 41 non-target coronary arterial lesions from 27 patients with ischemic heart disease were selected and examined. Thickness of 
the fibrous cap was measured by optical coherence tomography (OCT) at baseline and at 6 months follow up.
Results: Twenty-one fibroatheromas were identified in 13 diabetic patients and 20 fibroatheromas in 14 non-diabetic patients. During follow-up, 
overall fibrous cap thickness did not change significantly. Changes in fibrous cap thickness (Δfibrous cap thickness) was similar between non-
diabetic and diabetic patients (9.5±43.7 vs. -9.0±35.9 μm, p=0.14). In a subset of patients treated with pioglitazone, Δfibrous cap thickness was 
significantly greater than diabetic patients who are not treated with pioglitazone (5.5±27.3 vs. -25.0±38.7 μm, p<0.05).
Conclusions: Thickness of the fibrous cap decreases in diabetic patients who were not treated with pioglitazone. These results may 
explain higher incidence of ACS events in diabetic patients and may suggest favorable impact of the pioglitazone on plaque vulnerability. 
